Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) Net Income towards Common Stockholders: 2014-2025

Historic Net Income towards Common Stockholders for KalVista Pharmaceuticals (KALV) over the last 7 years, with Apr 2025 value amounting to -$42.3 million.

  • KalVista Pharmaceuticals' Net Income towards Common Stockholders rose 5.34% to -$42.3 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$156.4 million, marking a year-over-year decrease of 65.27%. This contributed to the annual value of -$183.5 million for FY2025, which is 44.86% down from last year.
  • According to the latest figures from Q2 2025, KalVista Pharmaceuticals' Net Income towards Common Stockholders is -$42.3 million, which was down 4.51% from -$40.4 million recorded in Q3 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Net Income towards Common Stockholders registered a high of -$29.0 million during Q1 2024, and its lowest value of -$44.6 million during Q2 2024.
  • Its 2-year average for Net Income towards Common Stockholders is -$39.1 million, with a median of -$41.4 million in 2024.
  • Data for KalVista Pharmaceuticals' Net Income towards Common Stockholders shows a peak YoY increased of 5.34% (in 2025) over the last 5 years.
  • Over the past 2 years, KalVista Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$40.4 million in 2024, then grew by 5.34% to -$42.3 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$42.3 million for Q2 2025, versus -$40.4 million for Q3 2024 and -$44.6 million for Q2 2024.